X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with ALEMBIC LTD - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs ALEMBIC LTD - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

ALEMBIC LTD 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA ALEMBIC LTD GSK PHARMA/
ALEMBIC LTD
 
P/E (TTM) x 63.5 122.5 51.8% View Chart
P/BV x 10.2 4.6 224.2% View Chart
Dividend Yield % 1.2 0.2 503.4%  

Financials

 GSK PHARMA   ALEMBIC LTD
EQUITY SHARE DATA
    GSK PHARMA
Mar-17
ALEMBIC LTD
Mar-16
GSK PHARMA/
ALEMBIC LTD
5-Yr Chart
Click to enlarge
High Rs3,83853 7,268.9%   
Low Rs2,63729 9,000.0%   
Sales per share (Unadj.) Rs354.24.7 7,504.5%  
Earnings per share (Unadj.) Rs39.88.8 453.2%  
Cash flow per share (Unadj.) Rs42.99.0 476.1%  
Dividends per share (Unadj.) Rs30.000.15 20,000.0%  
Dividend yield (eoy) %0.90.4 253.6%  
Book value per share (Unadj.) Rs236.927.7 854.5%  
Shares outstanding (eoy) m84.70267.03 31.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x9.18.7 105.1%   
Avg P/E ratio x81.44.7 1,740.1%  
P/CF ratio (eoy) x75.54.6 1,656.4%  
Price / Book Value ratio x13.71.5 922.9%  
Dividend payout %75.41.7 4,412.8%   
Avg Mkt Cap Rs m274,21610,962 2,501.6%   
No. of employees `0004.7NA-   
Total wages/salary Rs m4,830238 2,029.4%   
Avg. sales/employee Rs Th6,387.0NM-  
Avg. wages/employee Rs Th1,028.3NM-  
Avg. net profit/employee Rs Th717.1NM-  
INCOME DATA
Net Sales Rs m30,0001,260 2,380.4%  
Other income Rs m728264 276.0%   
Total revenues Rs m30,7281,524 2,016.1%   
Gross profit Rs m4,19083 5,060.1%  
Depreciation Rs m26361 428.3%   
Interest Rs m00 0.0%   
Profit before tax Rs m4,655285 1,633.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m02,096 0.0%   
Extraordinary Inc (Exp) Rs m457-32 -1,419.3%   
Tax Rs m1,7446 28,590.2%   
Profit after tax Rs m3,3682,343 143.8%  
Gross profit margin %14.06.6 212.6%  
Effective tax rate %37.52.1 1,749.8%   
Net profit margin %11.2185.9 6.0%  
BALANCE SHEET DATA
Current assets Rs m16,7421,689 991.4%   
Current liabilities Rs m7,202486 1,481.4%   
Net working cap to sales %31.895.4 33.3%  
Current ratio x2.33.5 66.9%  
Inventory Days Days52217 23.9%  
Debtors Days Days2181 25.6%  
Net fixed assets Rs m8,6351,624 531.7%   
Share capital Rs m847534 158.6%   
"Free" reserves Rs m19,2225,960 322.5%   
Net worth Rs m20,0697,404 271.1%   
Long term debt Rs m10104 9.6%   
Total assets Rs m30,0388,010 375.0%  
Interest coverage xNM950.7-  
Debt to equity ratio x00 3.5%  
Sales to assets ratio x1.00.2 634.8%   
Return on assets %11.229.3 38.3%  
Return on equity %16.831.6 53.0%  
Return on capital %25.531.3 81.4%  
Exports to sales %02.9 0.0%   
Imports to sales %028.9 0.0%   
Exports (fob) Rs mNA37 0.0%   
Imports (cif) Rs mNA364 0.0%   
Fx inflow Rs m52837 1,423.2%   
Fx outflow Rs m7,193365 1,971.0%   
Net fx Rs m-6,665-328 2,033.0%   
CASH FLOW
From Operations Rs m2,360346 682.9%  
From Investments Rs m3,008-48 -6,319.3%  
From Financial Activity Rs m-5,108-301 1,696.9%  
Net Cashflow Rs m260-3 -8,676.7%  

Share Holding

Indian Promoters % 0.0 64.0 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 0.2 5,100.0%  
FIIs % 23.8 9.7 245.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 26.1 59.0%  
Shareholders   102,036 54,701 186.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   PLETHICO PHARMA  BIOCON LTD  J.B.CHEMICALS  ALKEM LABORATORIES  AJANTA PHARMA  

Compare GSK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Marginally Lower; Capital Goods & Realty Stocks Fall(Closing)

Indian share markets witnessed selling pressure in the final hour of trade to finish just below the dotted line. At the closing bell, the BSE Sensex closed lower by 71 points.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Feb 20, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA 8-QTR ANALYSIS

COMPARE GSK PHARMA WITH

MARKET STATS